Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NicOx Adds Two Blood Pressure Monitoring Studies To Naproxcinod Program

This article was originally published in The Pink Sheet Daily

Executive Summary

Results of both blood pressure studies and two Phase III trials expected in 2008, positioning naproxcinod for mid-2009 filing.
Advertisement

Related Content

Naproxcinod Can Win Approval Without Superiority Trial, NicOx Says
Naproxcinod Can Win Approval Without Superiority Trial, NicOx Says
NicOx Gets Positive Results In Second Phase III Trial For Naproxcinod
NicOx Gets Positive Results In Second Phase III Trial For Naproxcinod
Pfizer Sees No Future In NicOx Glaucoma Candidate After Failure In Japanese Phase II Trial
Pfizer Sees No Future In NicOx Glaucoma Candidate After Failure In Japanese Phase II Trial
Pfizer Drops Phase II Glaucoma Candidate
NicOx On Track For First-Quarter 2009 Naproxcinod Filing
No Big Surprise For Novartis: Prexige Is “Not Approvable” At FDA
No Big Surprise For Novartis: Prexige Is “Not Approvable” At FDA

Topics

Advertisement
UsernamePublicRestriction

Register

PS067499

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel